Anti-MLKL antibody

• WB

Supplier Data

Western blot - Anti-MLKL antibody (AB183770)

Samples were separated by 10% SDS-PAGE.

All lanes:

Western blot - Anti-MLKL antibody (ab183770) at 1/500 dilution

Lane 1:

Jurkat whole cell extracts at 30 µg

Lane 2:

Raji whole cell extracts at 30 µg

Lane 3:

NCI-H929 whole cell extracts at 30 µg

Secondary

All lanes:

HRP-conjugated anti-rabbit IgG

Observed band size: 55 kDa

false

• WB

Supplier Data

Western blot - Anti-MLKL antibody (AB183770)

Samples were separated by 12% SDS-PAGE.

All lanes:

Western blot - Anti-MLKL antibody (ab183770) at 1/500 dilution

All lanes:

THP-1 Whole cell extract at 30 µg

Secondary

All lanes:

HRP-conjugated anti-rabbit IgG

Observed band size: 55 kDa

false

• WB

CiteAb

Western blot - Anti-MLKL antibody (AB183770)

MLKL western blot using anti-MLKL antibody ab183770. Publication image and figure legend from Su, W., Zhao, J., et al., 2020, Front Pharmacol, PubMed 32210806.

ab183770 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab183770 please see the product overview.

High-dose carteolol induced necroptotic protein expression in HCECs. (A) Western immunoblot images of RIPK1, RIPK3, MLKL and pMLKL proteins in 0.5–2% carteolol-treated HCECs. (B) The protein expression of RIPK1, RIPK3, MLKL and pMLKL were upregulated (P < 0.01), and the relative amount of each protein was expressed as a percentage (mean ± SD) of protein band density as compared that of β-actin at the same time-point (n = 3), while Nec-1 management manifested a significant inhibitory effect on the increased production of these proteins (P < 0.05 at the protein expression of RIPK3 with 2% cartelol-treated group, P < 0.01 at the other group). *P < 0.05, and **P < 0.01 vs control. (C) The activation of caspase-2 was measured by ELISA using monoclonal antibodies targeted against their active forms (P < 0.01). The 490 nm absorbance of each group was expressed as mean ± SD (n = 3). **P < 0.01 versus the blank control. (D) The caspase-8 was measured by ELISA using monoclonal antibodies targeted against their active forms (P < 0.05 at the caspase-8 activation with 2% cartelol-treated 2 h group, P < 0.01 at the other group). The 490 nm absorbance of each group was expressed as mean ± SD (n = 3). *P < 0.05, and **P < 0.01 versus the blank control.

false